Levodopa inhalation - Acorda Therapeutics

Drug Profile

Levodopa inhalation - Acorda Therapeutics

Alternative Names: CVT-301; Inhaled L-dopa - Civitas Therapeutics

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Civitas Therapeutics
  • Developer Acorda Therapeutics
  • Class Antiparkinsonians; Catecholamines; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Parkinson's disease
  • Phase I Asthma; Smoking withdrawal

Most Recent Events

  • 09 Feb 2017 Efficacy and safety data from the SPAN-PD phase III trial in Parkinson's disease released by Acorda Therapeutics
  • 09 Jan 2017 Acorda Therapeutics announces intention to submit MAA to EMA in 2017
  • 01 Dec 2016 Acorda Therapeutics completes a phase III trial for Parkinson’s disease (Adjunctive treatment) in Czech Republic, Poland and Spain (EudraCT2015-005067-17, NCT02240030)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top